Meningeal demyelination is associated with TNF, IFNγ, and CXCL13 in cerebrospinal fluid.
Patients with multiple sclerosis (MS) are more likely to have early onset aggressive disease if they have grey matter damage and meningeal demyelination. Whether these changes can be identified by markers in cerebrospinal fluid (CSF), especially early in the disease course, is unknown.
To find out, investigators tested postmortem samples from 27 patients with progressive MS and identified patients with either low or high densities of meningeal inflammation. Those with high meningeal inflammation had frequent aggregates of CD20+ B cells and CD3+ T cells in the subarachnoid space. Patients with high meningeal inflammation had worse disability (earlier age of wheelchair use and death) than the low-inflammation group. Gene expression for several…
Reviewing Author
DisclosuresConsultant/Advisory BoardAlexion Pharmaceuticals; Amgen; Astoria; Biogen; Bristol Myers Squibb; Celltrion; Genentech; Hoffmann-La Roche; Genzyme; EMD Serono; Immpact-Bio; Immunic Therapeutics; Kyverna; Lundbeck; Novartis; Sandoz; TG Therapeutics
Grant/Research SupportNational Institutes of Health; National Multiple Sclerosis Society; U.S. Department of Defense
Leadership Positions in Professional SocietiesConsortium of Multiple Sclerosis Centers (Treasurer)
DisclosuresConsultant/Advisory BoardAlexion Pharmaceuticals; Amgen; Astoria; Biogen; Bristol Myers Squibb; Celltrion; Genentech; Hoffmann-La Roche; Genzyme; EMD Serono; Immpact-Bio; Immunic Therapeutics; Kyverna; Lundbeck; Novartis; Sandoz; TG Therapeutics
Grant/Research SupportNational Institutes of Health; National Multiple Sclerosis Society; U.S. Department of Defense
Leadership Positions in Professional SocietiesConsortium of Multiple Sclerosis Centers (Treasurer)